CARPI Index for Predicting Cardiac Regeneration Potential
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the cardio-generative potential of mammalian cells, particularly cardiopoietic cells, are qualitative and time-consuming, making it difficult to predict the success of heart repair treatments before injection.
Innovation Solution
A method using the CARdiac generation Potential Index (CARPI) is introduced, which quantifies the expression of specific genes (Nkx2.5, Tbx5, MEF2C, GATA4, GATA6, Mesp1, FOG1) to assess the cardio-generative potential of cells, allowing for a predictive index of cardiac regeneration potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If qualitative assessment methods (immunocytochemistry, immunohistochemistry) are used to observe subcellular distribution of polypeptides, then the assessment can be performed, but the process is time-consuming and operator-dependent
Solution Approach 1:
The patent replaces manual microscopy observation with automated flow cytometry technology. Flow cytometry uses optical detection systems to automatically measure fluorescence or light scattering properties of cells, eliminating the need for manual imaging and subjective interpretation. This substitution of mechanical/optical automation for manual mechanical inspection directly addresses the time-consuming and operator-dependent nature of traditional methods while maintaining measurement precision through standardized quantitative parameters.
Solution Approach 2:
The patent transforms the assessment from qualitative observation of subcellular distribution to quantitative measurement of total protein content parameters. By changing the measurement parameter from spatial distribution patterns to integrated protein quantity, the method enables rapid automated assessment while maintaining predictive accuracy for cardio-generative potential. This parameter transformation allows objective, reproducible quantification that can be performed quickly without operator intervention.
2Loss of time
If western blotting or FACS are used to quantify total protein content, then the assessment is faster, but subcellular distribution information is lost
Solution Approach 1:
The patent extracts the essential functional information (total protein content relevant to cardio-generative potential) from the complex cellular system, separating this quantitative measure from the spatial distribution context. By taking out the key functional parameter (total protein content) rather than attempting to measure all aspects including subcellular location, the method achieves rapid assessment while retaining the critical information needed for predicting treatment outcome.
3Ease of manufacture
If naive human stem cells are used for heart repair, then the treatment is simple, but the cardio-generative potential cannot be predicted
Solution Approach 1:
The patent applies preliminary assessment of cardio-generative potential using flow cytometry before the actual heart repair treatment. By measuring total protein content parameters in advance, the system identifies patients with cells likely to succeed, enabling predictive selection. This preliminary action provides the missing information about treatment predictability while maintaining the simplicity of using naive stem cells, as the assessment adds no complexity to the cell therapy itself, only to the pre-treatment evaluation process.
Data Source
Figure 1
AI summary
This document is related to a method for determining the cardio generative potential of mammalian cells which comprises the assessment of a CARdiac generation Potential Index (CARPI) as a function of the quantification of the expression of genes of said cells. It also relates to a method for quantitatively assessing the modification of this cardio-generative potential and the cardiogenic potential of a treatment aiming at cellular differentiation.